Project Grant R03CA286683
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$160K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research aimed at elucidating the molecular and cellular mechanisms driving changes in chromatin state and immune response, and how they shape tumor heterogeneity and progression in lung and pancreatic ductal adenocarcinomas. The $0.00 award, spanning from September 1, 2024 to August 31, 2028, will be administered by the Whitehead Institute for...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,063,710 to The Johns Hopkins University to investigate the epigenetic mechanisms controlling single-stranded DNA lesion sensitivity and mutagenesis. The research aims to define the epigenetic pathways that regulate single-stranded DNA lesion repair, with a focus on the role of histone variant MacroH2A1 isoforms. The project will examine how changes in MacroH2A1 splicing...
This Project Grant award of $254,919 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training (CFDA 93.859) federal grant program, aims to advance the understanding of regulatory mechanisms that ensure accurate transmission of the genome during cell division. The key focus areas are: 1) Investigating how cells regulate the loading and removal of the Mini-Chromosome Maintenance (MCM) complex to prevent incomplete DNA replication, a major...
This Project Grant award, valued at $775,170, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program. The funding supports research by the University of California, San Diego (UCSD) to investigate the organization and function of regulatory DNA, which controls gene expression patterns during development and in response to stimuli. Using experimental and computational approaches, the research aims to...
This Project Grant award of $563,663 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the discovery of small molecules targeting Polycomb Repressive Complexes 1 and 2 (PRC1 and PRC2) for potential cancer therapeutic applications. The overarching objective is to identify diverse small molecules with activity against canonical PRC1 (cPRC1) and determine their mechanisms of action, as an alternative to targeting the PRC2 subunit EZH2...
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $667,480 to St. Jude Children's Research Hospital Inc. to conduct structural and functional studies of chromatin. The research aims to understand how chromatin dynamics and histone modifications regulate genome expression, which may uncover new approaches for cancer treatment. The award period runs from May 1, 2025...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to understand the mechanisms by which a gene essential for rhabdoid tumor viability regulates chromatin function. The $148,568 award to St. Jude Children's Research Hospital will fund a 2.5-year project starting on Dec 25, 2024. The research aims to elucidate how loss of the target protein disrupts the balance between the SWI/SNF chromatin remodeling complex and the polycomb...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying chemical compounds that inhibit the chromatin reader SGF29, which regulates the transcription of oncogenes in acute myeloid leukemia (AML). The research project will implement high-throughput screening assays developed by the institute to screen chemical libraries and identify...
This Project Grant award under the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $162,115 to the University of Florida Health Cancer Center from September 1, 2024 to August 31, 2029. The award supports the research work of Dr. Bennett, a cancer research specialist, who will lead teams investigating epigenetic mechanisms of cancer. The funded research aims to reveal new epigenetic mechanisms driving tumor progression, heterogeneity, and therapy resistance,...